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Abstract
Embryonic stem (ES) cells hold immense promise for the treatment of human degenerative disease.
Because ES cells are pluripotent, they can be directed to differentiate into a number of alternative
cell-types with potential therapeutic value. Such attempts at "rationally-directed ES cell
differentiation" constitute attempts to recapitulate aspects of normal development in vitro. All
differentiated cells retain identical DNA content, yet gene expression varies widely from cell-type
to cell-type. Therefore, a potent epigenetic system has evolved to coordinate and maintain tissue-
specific patterns of gene expression. Recent advances show that mechanisms that govern
epigenetic regulation of gene expression are rooted in the details of chromatin dynamics. As
embryonic cells differentiate, certain genes are activated while others are silenced. These activation
and silencing events are exquisitely coordinated with the allocation of cell lineages. Remodeling of
the chromatin of developmentally-regulated genes occurs in conjunction with lineage commitment.
Oocytes, early embryos, and ES cells contain potent chromatin-remodeling activities, an
observation that suggests that chromatin dynamics may be especially important for early lineage
decisions. Chromatin dynamics are also involved in the differentiation of adult stem cells, where
the assembly of specialized chromatin upon tissue-specific genes has been studied in fine detail. The
next few years will likely yield striking advances in the understanding of stem cell differentiation and
developmental biology from the perspective of chromatin dynamics.
Embryonic stem cells: promise and challenge
Recent interest in both scientific and lay communities has
centered on the potential use of embryonic stem (ES) cells
as therapeutic agents for the treatment of degenerative
human diseases. This excitement stems from the pluripo-
tent nature of ES cells, which allows them to differentiate
into a broad spectrum of cell-types that may one day be
used for transplantation purposes (Fig. 1). ES cell lines are
derived from explanted culture of the inner cell mass
(ICM) of blastocyst-stage embryos. In normal develop-
ment, the ICM is the primordial source of the entire
embryo proper, while the trophectoderm and maternal
cells contribute to the placenta. ES cells can be maintained
in an undifferentiated (and pluripotent) state by culture
in the presence of the cytokine LIF (leukaemia inhibitory
factor).
A great variety of cell-types have been generated by the dif-
ferentiation of ES cells in vitro. Such cell-types resemble
neuronal cells, pancreatic cells, muscle cells and fibrob-
lasts, hematopoietic cells, and many others, but it is
unclear at present how closely these cells mimic their nor-
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mal counterparts created in the course of development in
vivo. Indeed, many promising derivatives of ES cells have
proven to function poorly in animal engraftment models.
These difficulties point to the need for a more
sophisticated understanding of the differentiation process
and the development of new methods to more exhaus-
tively assess the identities of cells generated by in vitro dif-
ferentiation. Future methods that achieve successful
directed differentiation will rely heavily on a thorough
understanding of the developmental pathways that they
attempt to recapitulate. Initial attempts to bring stem cell
therapy to a state of effectiveness have been hampered by
a paucity of knowledge concerning the underlying mech-
anisms that govern differentiation.
Epigenetic management of the genome through 
chromatin
Adult mammals contain hundreds of cell-types distrib-
uted among their organs, each with identical DNA con-
tent. Yet each of these cell-types has a unique pattern of
gene expression. The field of epigenetics is concerned with
influences on gene expression that occur independently of
DNA sequence per se. In principle, genes behave in three
ways during development: Some genes are subject to line-
Stem cell therapy viewed from the standpoint of developmental biology Figure 1
Stem cell therapy viewed from the standpoint of developmental biology. Early mammalian embryonic development 
involves a series of rapid symmetric cell divisions leading to morula formation. Subsequently, blastocyst-stage embryos form 
with two cell-types: the trophectoderm (TE), which develops into the embryonic portion of the placenta, and the inner cell 
mass (ICM), which develops into the embryo proper. Immortal embryonic stem (ES) cells are derived from the ICM, and retain 
developmental totipotency. In vitro differentiation protocols yield a variety of unique cell-types that are potentially useful as 
clinical transplantation materials.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/100
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age-dependent activation events, while others undergo
lineage-dependent silencing events, such as X chromo-
some inactivation and silencing of embryonic genes such
as Oct 4 [1]. Lastly, the expression of housekeeping genes
is maintained constitutively (Fig. 2). Though each cell has
identical DNA content, the way in which it is packaged
with chromosomal proteins (i.e. chromatin) differs
greatly from cell to cell. Indeed, recent findings from chro-
matin research and animal cloning (nuclear transfer)
studies suggest that much of the molecular basis of tissue-
specific gene expression is rooted in the details of chroma-
tin structure.
The basic subunit of all chromatin is the nucleosome,
which consists of a histone octomer containing a pair of
each of the standard histones H2A, H2B, H3, and H4 and
146 base pairs of DNA. Chromatin can be broadly divided
into two fractions: euchromatin, which is permissive for
transcription, and heterochromatin, which is repressive.
Heterochromatin itself occurs in two varieties, constitu-
tive and facultative. DNA within constitutive heterochro-
matin is obligately silenced. Examples include
centromeric regions and inactivated repetitive elements
such as Alu, LINE, and SINE elements, and inactivated ret-
roviruses. In contrast, facultative heterochromatin is
Epigenetic management of the genome Figure 2
Epigenetic management of the genome. An idealized chromosome is depicted with genes that are either transcribed 
(green) or silenced (red). As cells undergo developmentally-regulated changes in lineage (in either normal development or in 
the context of ES cell differentiation), patterns of gene expression change. Genes can be specifically silenced or activated 
through epigenetic means facilitated by chromatin remodeling (left lineage). Once terminally differentiated states are reached, 
patterns of gene expression can be maintained in a metastable fashion through maintenance of chromatin configuration (right 
lineage).Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/100
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silenced only in certain contexts. Examples of facultative
heterochromatin include tissue-specific genes that are
silenced in all but the appropriate tissue, and X chromo-
somes in female eutherian mammals, which can be either
active or silenced for reasons of dosage compensation.
Heterochromatin seems to have much more molecular
complexity than euchromatin. Most euchromatin consists
of standard nucleosomes, but heterochromatin often con-
tains modified nucleosomes in which histone variants
substitute for standard histones. Examples include the his-
tone H2A variants macroH2A1 [2] and macroH2A2 [3,4],
the histone H3 variant CENP-A [5,6] which associates
with centromeric heterochromatin, and histones H2A.X
and H2A.Z. Histone H2A.X becomes phosphorylated
when DNA is damaged and marks sites of double-
stranded breaks in DNA [7], while H2A.Z protects euchro-
matin from becoming transcriptionally inactive [8].
Chromatin is further modified by the addition of post-
translational modifications upon histones such as
methyl-, acetyl-, phosphoryl-, and ADP ribosyl-groups
(see reviews: [9-11]). Histone modifications can serve as
cis-acting binding sites for auxiliary factors such as hetero-
chromatin protein 1 (HP1), which binds to histone H3
upon methylation at lysine 9 [12,13], a key bimolecular
interaction in heterochromatin that is controlled by
Suv39h1 and Suv39h2 histone methyltransferases [14-16].
Histone methylation also occurs upon histone H3 at the
lysine 4 position, but in this case, methylation correlates
with transcriptional activity [17]. DNA itself can also be
methylated, primarily upon cytosines within CpG dinu-
cleotides. Here too, methylation serves to foster bimolecu-
lar interactions between heterochromatin and auxiliary
proteins such as MeCP2, and MBD1, 2, and 3. On a
molecular level, close connections exist between chroma-
tin and the transcriptional apparatus. The importance of
transcription factors for gene activation is indisputable,
but a remarkable number of transcription factors are now
known to interact with transcription-promoting histone
acetyltransferase (HAT) proteins [18]. An emerging view is
that histone modifications may serve as "switches" to acti-
vate or repress gene expression, in much the same way
that phosphates toggle the activation or repression of
intracellular signal transduction pathways.
Embryonic cells contain robust chromatin-
remodeling and reprogramming activities
As ES cells undergo differentiation, they spontaneously
execute developmentally-regulated programs of gene
expression and gene silencing that are intimately coordi-
nated with alterations in chromatin structure. Perhaps the
best studied of these is X chromosome inactivation (XCI),
where a number of step-wise chromatin remodeling
events lead to the formation of stably-silenced X chromo-
somes in differentiating female ES cells. The initiation
step of X inactivation is governed by a mutually-antago-
nistic expression pattern involving the genes Tsix and Xist,
which lie adjacent to one another within the X inactiva-
tion center (XCI) of the X chromosome [19]. Tsix and Xist
give rise to overlapping untranslated RNA transcripts that
are retained upon X chromosomes by an unknown mech-
anism. In undifferentiated cells, Tsix expression prevents
the accumulation of Xist RNA. As differentiation com-
mences, Tsix expression is extinguished from the future
inactive X chromosome (Xi), which allows Xist to accu-
mulate, spread, and coat the Xi. Expression of Xist RNA is
required for initiation of X inactivation but not its main-
tenance [20,21]. Shortly after Xist coating, the silencing of
X-linked genes can be detected, but this early silencing is
unstable and reversible [22]. A number of subsequent
(and ordered) chromatin remodeling events then occur to
stabilize the inactive state. These include a transient asso-
ciation of the histone methyltransferase complex Eed-
Ezh2 which methylates histone H3 at lysine 27 [23,24].
Another early event in X chromosome inactivation is late
replication timing of Xi relative to the active X during S
phase of the cell cycle [25,26]. Subsequently, histones
become hypoacetylated [27,28] upon lysine residues and
methylated at lysine 9, an event probably performed by
the Suv39h1 and h2 histone methyltransferases [29,30].
Later, the histone variant macroH2A is incorporated into
inactivated X chromosomes within female nuclei. These
local macroH2A concentrations are called macrochroma-
tin bodies (MCBs) [31]. MCB formation occurs relatively
late in the X chromosome inactivation process [32,33],
and requires prior expression of Xist [20,34]. Recent evi-
dence points to a functional role for macroH2A1 in gene
silencing since it can cause down-regulation of reporter
gene activity [35]. In addition, macroH2A1 can inhibit
binding of the transcription factor NF-kappaB and retards
the action of SWI/SNF chromatin remodeling complexes
[36]. A final step in the X inactivation process is marked
by the methylation of the CpG islands of silenced X-
linked genes [37]. Interestingly, all of these chromatin-
remodelling events (with the exception of the action of
the Tsix/Xist RNAs) can also occur on autosomes [38].
Therefore, it seems that all post-RNA events of XCI may
have been co-opted from pre-existing autosomal systems
during the evolution of XCI in placental mammals.
Interestingly, the mammalian nuclear transfer cloning
process can reprogram X chromosome inactivation. In
this case, inactive X chromosomes from somatic cells were
reactivated in cloned embryos but not trophectoderm
[39]. Though cloned embryos transit the blastocyst devel-
opmental stage (with concomitant formation of the ICM),
it is unclear at which stage the somatic donor XCI status
was erased (or reactivated), though failure of erasure to
occur in trophectodermal cells suggests the possible
involvement of the ICM cells or their progenitors in repro-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/100
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gramming events. Another interpretation of these results
is that the somatic pattern of XCI is read out in the troph-
ectoderm much like an imprint, a distinct possibility since
XCI is imprinted only in the extra-embryonic tissues in the
mouse. In either case, it is clear that reprogramming of
inactive X chromosomes during the cloning process
shows that oocytes or primitive embryonic cells have
extensive chromatin remodeling activity.
Mammalian cells contain a variety of chromatin remode-
ling complexes, which typically are composed of several
proteins. Inactivation of chromatin remodeling com-
plexes usually results in developmental arrest at about the
blastocyst stage. For instance, loss of SNF5, a shared com-
ponent of two related mammalian SWI/SNF chromatin
remodeling complexes causes developmental arrest at
about the time of embryo implantation and is required for
ES cell viability [40]. Homozygous deletion of SNF2β
(another component of mammalian SWI/SNF chromatin
remodeling complexes), leads to lethality in F9 embryo-
nal carcinoma cells [41]. The polycomb group gene rae28
is required for efficient renewal of hematopoietic stem
cells [42], while the polycomb group gene Ezh2 (which
contains a histone methyltransferase SET domain) is
required for post-implantation development and ES cell
viability [43].
Direct demonstrations of reprogramming activities within
ES cells come from experiments involving intentional cell
fusions between ES and somatic cells. Fusions between
male ES cells and adult female thymocytes led to demon-
strated alterations in the chromatin of inactivated X chro-
mosomes originating from the thymocyte nucleus. These
alterations included the abolition of late replication tim-
ing of the thymocyte Xi, and destabilization of the Xist
RNA transcript. In addition, a silenced Oct4-GFP trans-
gene was reactivated in these fusion cells, a transcriptional
state reminiscent of primitive cells [44]. Significantly, ES-
thymocyte fusions gained pleuripotency since they con-
tributed to all three germ layers in chimeric embryos [44].
However fusions between ES cells and thymocytes failed
to alter methylation of the imprinted Igf2-H19  region,
which occurs readily when embryonic germ cells and thy-
mocytes are fused [45].
Hints from adult stem cells and developmental 
biology
Studies of adult stem cells provide ample evidence that
chromatin functions in specialized differentiation events.
A classic view of development posits that the commitment
of primitive multipotent cells to specific lineages is medi-
ated by key transcription factors that activate downstream
tissue-specific genes. For instance, retroviral-mediated
transfer of transcription factor MyoD into a variety of non-
muscle cell types can convert them into cells that resemble
striated myoblasts as judged by cellular morphology and
expression of muscle-specific markers [46]. This is but one
of many demonstrations that transcription factors can
effectively initiate developmental programs that culmi-
nate in directed differentiation (even trans-differentia-
tion) of cells. In contrast, recent evidence shows that
heterochromatin formation can be a key mechanism for
lineage restriction during development.
The differentiation of hematopoietic stem cells (HSCs)
seems to occur by means of selective silencing (i.e. restric-
tion) of lineage-specific genes. Hematopoietic stem cells
and their immediate progenitors exhibit a promiscuous
pattern of gene expression. Uncommitted HSCs simulta-
neously express genes previously thought to be tran-
scribed exclusively in either the myeloid or erythroid
lineages [47]. Developmentally-regulated restriction of
gene expression also occurs during formation of glial cells
of the brain. The formation of oligodendrocytes from glial
cell precursors requires exit from mitosis and histone
deacetylase (HDAC) activity shortly thereafter. Oli-
godendrocyte formation is abolished by use of the HDAC
inhibitor trichostatin A, suggesting that hypoacetylation
of histones in glial stem cells is a normal occurrence dur-
ing neurogenesis [48].
The regulation of globin gene expression is also mediated
by chromatin remodeling. The locus control region (LCR)
is a non-coding regulatory domain that lies adjacent to the
globin gene cluster. Lineage-specific expression of globin
genes is modulated by a complex set of chromatin events
involving the LCR and individual globin gene promoters.
Interestingly, DNase I sensitive sites within the LCR that
are observed in erythrocyte lineages can be found much
earlier in multipotent hematopoietic stem cells, suggest-
ing that chromatin rearrangements precede transcrip-
tional activation of lineage-specific genes during
hematopoiesis [49]. This "primed" configuration of the
LCR is also evident in embryonic yolk sac, where
acetylated histones are present at the LCR and globin gene
promoters (whether active or inactive) while in brain, the
LCR is hypoacetylated and globin genes are transcription-
ally silent [50]. Interestingly, the LCR is present in an
acetylated state in ES cells [51]. Together, these data
suggest that aspects of globin gene expression may be reg-
ulated by a restriction mechanism involving the LCR.
Finally, the intranuclear position of chromatin seems to
have a bearing on its regulation. In many mammalian cell
types, it has been observed that transcriptionally silent
genes reside in a position near the nuclear periphery [52],
or interphase centromeres (chromocenters) [53], while
active genes are maintained near the center of nuclei.
Nuclear location of genes may therefore lead to changes in
their transcription state and there is some evidence thatReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/100
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this is a dynamic process. For instance, the zinc-finger pro-
tein Ikaros is expressed in lymphoid cells and seems to be
a regulator of gene silencing by recruiting genes to repres-
sive heterochromatin [54]. Deletion of Ikaros leads to a
loss of differentiative potential in hematopoietic stem
cells in mice [55].
Conclusions
The dynamic assembly and disassembly of specialized
chromatin is a likely mechanism for the epigenetic regula-
tion of gene expression during ES cell differentiation and
development in vivo. Put another way, the transcriptional
state of a gene can be viewed as a reflection of its underly-
ing chromatin state. Indeed, it seems possible that all stem
cells share common epigenetic mechanisms given the
recent demonstration that hematopoietic, neural, and
embryonic stem cells express a significant number of non-
housekeeping genes in common [56]. Because stem cell
differentiation is essentially an attempt to achieve tissue-
specific patterns of gene expression in vitro, it seems rea-
sonable that studies of chromatin in differentiating ES
cells will greatly aid the subsequent clinical development
of stem cell therapies. The analysis of chromatin factors
and modifications that exhibit tissue-specific genomic
distribution patterns will likely yield substantial insights
into the use of stem cells of all types.
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